Publications

1 2 3 4 5 6 7 8 12 23 33 44

Lukas Rob, David Cibula, Pawel Knapp, Peter Mallmann, Jaroslav Klat, Lubos Minar, Pavel Bartos, Josef Chovanec, Petr Valha, Marek Pluta, Zdenek Novotny, Jiri Spacek, Bohuslav Melichar, Dariusz Kieszko, Jitka Fucikova, Tereza Hrnciarova, Roman Pawel Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek.

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

J Immunother Cancer. 2022 Jan;10(1):e003190. doi: 10.1136/jitc-2021-003190.

Jitka Fucikova, An Coosemans, Sandra Orsulic, David Cibula, Ignace Vergote, Lorenzo Galluzzi, Radek Spisek.

Immunological configuration of ovarian carcinoma: features and impact on disease outcome

J Immunother Cancer. 2021 Oct;9(10):e002873. doi: 10.1136/jitc-2021-002873.

David Cibula, Lukas Rob, Peter Mallmann, Pawel Knapp, Jaroslav Klat, Josef Chovanec, Lubos Minar, Bohuslav Melichar, Alexander Hein, Dariusz Kieszko, Marek Pluta, Jiri Spacek, Pavel Bartos, Pauline Wimberger, Radoslaw Madry, Janina Markowska, Joanna Streb, Petr Valha, Hariz Iskandar Bin Hassan, Ladislav Pecen, Lorenzo Galluzzi, Jitka Fucikova, Tereza Hrnciarova, Marek Hraska, Jirina Bartunkova, Radek Spisek.

Dendritic cell-based immunotherapy (DCVAC/OvCa) combined with second-line chemotherapy in platinum-sensitive ovarian cancer (SOV02): A randomized, open-label, phase 2 trial

Gynecol Oncol. 2021 Sep;162(3):652-660. doi: 10.1016/j.ygyno.2021.07.003. Epub 2021 Jul 20.